LeMaitre Vascular, Inc. (LMAT)
Nasdaq · Healthcare · Medical Instruments & Supplies
$80.99+2.57%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $1.9B
- P/E (trailing)
- 28.4
- Forward P/E
- 25.5
- Dividend yield
- 1.2%
- 52-week range
- $78.22 – $118.01
- 52-week change
- −9.02%
- EPS (trailing)
- $2.85
- Analyst rating
- 2.3 Buy
- Next earnings
- Nov 5, 2026
Fiscal year to Dec 2025
- Revenue
- $250M (+13.53%)
- Net income
- $57.7M
- Operating margin
- 27.2%
- Diluted EPS
- $2.52
- Free cash flow
- $74.5M
From the company’s annual report on SEC EDGAR.
About LeMaitre Vascular, Inc.
LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery in the Americas, Europe, the Middle Esat, Africa, and the Asia Pacific. The company offers allografts, which are cryopreserved human tissue grafts used in vascular reconstruction, and cardiac repair and reconstruction; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature, as well as human cadaver tissue cryopreservation services.
Headquarters: Burlington, United States · 646 employees · lemaitre.com